Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
De Novo Design of Senescence-Associated Secretory Phenotype Cytokine Super-Antagonists
FY 2025-26
Summary
A major driver of age-related chronic diseases such as cancer, diabetes, and cardiovascular disease are 'zombie cells', also termed senescent cells. They don't divide or die, but release large amounts of inflammatory molecules, known as the senescence-associated secretory phenotype (SASP), that lead to tissue dysfunction and disease.
Unfortunately, there are currently no approved therapeutics to reduce or eliminate senescent cells. Existing small molecule and antibody approaches suffer from several limitations including poor specificity, high cost, toxicity, and risk of immune response. Thus, there is an urgent need for novel therapeutics that target senescent cells.
Recent advances in protein design have enabled the design of a new class of drugs called miniproteins. These are small, stable, synthetic proteins which can be computationally designed to tightly bind specific targets while being cheaper to produce and safer. As such, my research aims to develop miniproteins that can block SASP inflammatory molecules, preventing them from perpetuating harmful signals that drive chronic diseases. To do this, I will first use AI-guided tools to design miniproteins that bind to the most highly expressed SASP inflammatory molecules, such as IL-6, IL-8, and IL-1B. After validating that they can bind their intended targets, I will use mouse models to test whether they can reduce inflammation and prevent senescent cell-driven tumor growth.
Ultimately, this research aims to develop a novel therapeutic strategy that targets the harmful effects of senescent cells to alleviate chronic disease burden and extend healthspan.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572982
Name
Yuan Kevin D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
De Novo Design of Senescence-Associated Secretory Phenotype Cytokine Super-Antagonists
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cellular Senescence; Chronic Disease; Computational Protein Design; Il-1b; Il-6; Il-8; Pro-Inflammatory Cytokines; Protein Engineering; Senescence-Associated Secretory Phenotype; Senomorphics
Abstract
A major driver of age-related chronic diseases such as cancer, diabetes, and cardiovascular disease are 'zombie cells', also termed senescent cells. They don't divide or die, but release large amounts of inflammatory molecules, known as the senescence-associated secretory phenotype (SASP), that lead to tissue dysfunction and disease.
Unfortunately, there are currently no approved therapeutics to reduce or eliminate senescent cells. Existing small molecule and antibody approaches suffer from several limitations including poor specificity, high cost, toxicity, and risk of immune response. Thus, there is an urgent need for novel therapeutics that target senescent cells.
Recent advances in protein design have enabled the design of a new class of drugs called miniproteins. These are small, stable, synthetic proteins which can be computationally designed to tightly bind specific targets while being cheaper to produce and safer. As such, my research aims to develop miniproteins that can block SASP inflammatory molecules, preventing them from perpetuating harmful signals that drive chronic diseases. To do this, I will first use AI-guided tools to design miniproteins that bind to the most highly expressed SASP inflammatory molecules, such as IL-6, IL-8, and IL-1B. After validating that they can bind their intended targets, I will use mouse models to test whether they can reduce inflammation and prevent senescent cell-driven tumor growth.
Ultimately, this research aims to develop a novel therapeutic strategy that targets the harmful effects of senescent cells to alleviate chronic disease burden and extend healthspan.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yuan, Kevin D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~